News | Blood Testing | March 01, 2017

New Heart Attack Evaluation Cuts Unnecessary Tests, Time in ER

Safe approach could help nearly 10 million Americans seen each year for chest pain

heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study

March 1, 2017 — Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a highly sensitive, newly U.S. Food and Drug Administration (FDA)-approved blood test and a heart health scoring system. These findings were drawn from an international study led by Henry Ford Health System.

That is good news for 8 to 10 million Americans seen for chest pain each year in emergency rooms, said Henry Ford cardiologist James McCord, M.D. Studies show a heart attack is ruled out for about 85 percent of those patients.

“People can appreciate if you’re in the ER for two hours versus 30 hours — that’s a big deal,” said McCord, estimating that about 40 percent — or approximately 3.5 million patients — who pass the testing could go home quickly. “The patients not only have a heart attack ruled out, they represent a low-risk group of patients who can go home from the ER without further observation or cardiac testing, like a stress test.”

The study was recently published online and will appear in the March print issue of the American Heart Association’s Circulation: Cardiovascular Quality and Outcomes. Twelve hospitals around the world participated, including Henry Ford and the University of Maryland in the United States.

Emergency rooms around the world for years have been diagnosing heart attacks using a blood test that measures the protein troponin, which the heart releases during a heart attack. But a more sensitive troponin test available in Europe and other parts of the world was just approved for use in the United States by the FDA in February.

For the study, the researchers focused on 1,282 patients from 2011 through 2013 who had chest pain and were evaluated in emergency rooms for possible heart attacks. For this study, and separately from the patients’ medical treatment, the researchers asked the patients for permission to test their blood using the new, sensitive troponin test. The researchers also scored the patients with a heart health evaluation called the Heart Score. The Heart Score looks at the patient’s heart health history, the results of an electrocardiogram (ECG) done in the ER, the person’s age, and their risk factors like smoking, hypertension and diabetes.

Within 30 days, 217 of the patients had either a heart attack or died. In the 515 patients that had a low Heart Score and normal troponin blood tests over 1 hour, the chance of a heart attack or death at 30 days was only 0.2 percent.

Those are the patients — 40 percent of patients in the study — that likely could safely go home quickly, saving time and thousands of dollars for both the patients and hospitals, said McCord.

“Currently, many of these patients stay in an observation unit for hours, then get a stress test or cardiac imaging, which takes a day or more to accomplish,” said McCord. “It’s huge not only from the hospital perspective because it takes time and money to hold the patients, get a test, review the tests and make a decision — there is the time that the patient is out of the workforce. If you put that into the equation, that’s another large part of the financial impact equation.”

Now that the more sensitive troponin test is offered in the United States and ER evaluation data is available, McCord said hospitals will be deciding how to move forward. The new troponin test requires the addition of testing equipment.

“It’s showing where we are headed in the future,” said McCord. “Institutions, including our own, are looking at the data and deciding how to incorporate it into our patient evaluation. There wasn’t even the availability of using it until very recently. We’re behind the rest of the world; now the door’s opening for us to use these novel tests.”

Read the article "Highly-sensitive Troponin Test Can Detect Myocardial Injury After Non-Cardiac Surgery."

Read the article “Common Troponin Blood Test May Predict Future Hypertension.”

Read the article “New Data for Abbott's Investigational High Sensitive Troponin Test May Help Predict Heart Attack Risk”

For more information:


McCord, J., Cabrera, R., Lindahl, B., Giannitsis, E., et al. "Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department," Circulation: Cardiovascular Quality and Outcomes. Published online Feb. 6, 2017. DOI:

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init